Cardiff Oncology Inc
CRDF
View Detailed Chart
1.600USD
+0.120+8.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
107.35MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.11%
5 Days
-8.57%
1 Month
-50.16%
6 Months
-33.61%
Year to Date
-43.06%
1 Year
-64.44%
View Detailed Chart
TradingKey Stock Score of Cardiff Oncology Inc
Currency: USD Updated: 2026-02-06Key Insights
Cardiff Oncology Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 129 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.38.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardiff Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Cardiff Oncology Inc Highlights
StrengthsRisks
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 76.94% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 683.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 683.00K.
Fairly Valued
The company’s latest PE is -2.02, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.08M shares, decreasing 0.00% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.84K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.06.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
10.375
Target Price
+556.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cardiff Oncology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardiff Oncology Inc Info
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Ticker SymbolCRDF
CompanyCardiff Oncology Inc
CEOErlander (Mark)
Websitehttps://cardiffoncology.com/
Related Instruments
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70120.000
+518.820 (+0.74%)
282.580
+22.390 (+8.61%)
2090.260
-12.560 (-0.60%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
